drugset / Trial / NCT06765915
Avapritinib Maintenance for AML With KIT Mutations
NaSingle-groupOpen-labelTreatment
Summary
A multicenter, single-arm clinical study of evaluate the efficacy and safety of avapritinib as maintenance therapy following allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with KIT mutation.
Timeline
- Start
- 2025-02-01
- Primary completion
- 2026-02-01
- Completion
- 2028-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avapritinib | Small molecule | 100 mg | Oral |